Sunday, February 18, 2018

NILOTINIB- anticancer drugs

INTRODUCTION
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). In June 2006, a Phase I clinical trial found nilotinib has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (Gleevec®), another tyrosine kinase inhibitor currently used as a first-line treatment.

PHARMACOLOGICAL ACTION
For the potential treatment of various leukemias,including chronic myeloid leukemia (CML). Nilotinib is a transduction inhibitor that targets BCR-ABL, c-kit and PDGF, for the potential treatment of various leukemias, including chronic myeloid leukemia (CML).

USES
Used in treatment of Philadelphia chromosome positive chronic myelojenous leukemia.
Used in treatment of Parkinson’s and Alzimer’s disease.

SIDE EFFECT
Muscle pain
Rash
Arrythmia
GIT problems

DRUG DRUG INTERACTION
Avanafil + nilotinib= The serum concentration of avanafil can be increased
Bexarotene+ nilotinib= The serum concentration of nilotinib can be decreased

REFERENCE
Tripathi K.D,"Essentials of medical pharmacology",7th edition,page no 858,870

No comments:

Post a Comment